Lv2
140 积分 2024-09-02 加入
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
12小时前
已完结
A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib, for Glucocorticoid-Refractory or -Dependent Chronic GVHD
3天前
已完结
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin‐4‐IgG4‐Fc in healthy subjects: A phase 1, single‐centre, randomized, double‐blind, dose escalation study
3个月前
已完结
A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors
9个月前
已完结
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
11个月前
已完结
Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets
11个月前
已完结
Lecanemab in Early Alzheimer’s Disease
11个月前
已完结
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
11个月前
已完结
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
11个月前
已关闭
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
11个月前
已关闭
皖公网安备34019202002308
